Caliper Life Sciences Expands Labchip GX Product Capabilities

Caliper Life sciences, has launched two new products that expand the LabChip GX product line: a GLP/GMP-compliant version of the operating software for the LabChip GX instrument that is amenable to manufacturing QC environments and a new protein assay with higher, silver stain levels of sensitivity. The LabChip GX platform has been adopted by biopharmaceutical companies and academic institutions for protein therapeutics, vaccines, and nucleic acid applications.

Caliper is working closely with biopharmaceutical analytical development groups to optimize its LabChip platforms for the characterization of biologicals and to expand the application breadth of these platforms.

Kevin Hrusovsky, CEO of Caliper Life Sciences, said: “Our LabChip GX platform provides unique speed, throughput, cost, and data quality advantages for biologicals and has just begun to be adopted by vaccine producers.

“The LabChip GX is ideally suited for high throughput characterization of subunit and virus-like particle vaccines, which have emerging uses for the H1N1 influenza, or swine flu, and similar viruses. The LabChip EZ Reader platform is being used to identify small molecule antiviral drugs that inhibit viral proteases.

“We also plan to launch a high throughput glycan profiling reagent kit for seven different sugar groups this quarter to address a growing assay requirement for characterization of biologicals and vaccines. These revolutionary capabilities have led to the rapid adoption of the LabChip GX platform.”